SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: hillary kapan who wrote (116)6/19/1997 7:59:00 AM
From: r. peter Dale   of 4474
 
Hilary: One possible explanation for the failure of well informed followers of Ariad to mention the various research aspects of the Company (combi-chem, structure-based drug design, etc..) is that they all pertain to the same premise: targeting the SH2, SH3, and/or kinase subdomains of specific proteins to inhibit catalytic activity. Achieving this sort of pinpoint regulation would clearly be of significance. Since there are a large number of intercellular proteins containing these domains, and these proteins subserve vital cellular processes, establishing specificity and, more importantly, confirming this discrete targeting in vivo , will be...challenging.

I've yet to read the literature noted on Ariad's web site; I'm curious to learn of the diversity of these binding domains which allows such directed drug design. Can anyone provide a specific example of such targeting in an animal model (i.e. in vivo )?

Best wishes,
Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News